Baxter International Inc (BAX)
Sous-évaluéFondamental
41
Prix
$23.64
Capitalisation boursière
$12.14B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 septembre 2026 with claude-haiku-4-5 — shared with all users
ICU Medical sells IV solutions, infusion pumps and administration sets to the same US hospital pharmacies and supply contracts that Baxter's Medical Products & Therapies segment depends on.
BD competes head-on with Baxter for hospital infusion contracts with its Alaris smart pumps, IV sets and injectable drug delivery lines.
Stryker is the closest rival to Baxter's Hillrom business for smart hospital beds, patient monitoring and operating-room equipment bought by the same acute-care hospitals.
The German family-owned group offers the same sterile IV fluids, infusion pumps and parenteral nutrition range, and is Baxter's main rival for European hospital tenders.
Fresenius Kabi competes with Baxter both in IV fluids and parenteral nutrition and in specialty injectable generics sold to hospital pharmacies.
Bilan & Liquidités
Chiffre d'affaires
$11.47B
12 derniers mois (au 30/06/2026)
Résultat net
$-1.06B
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$332M
Capitaux propres totaux
$6.13B
Passif total
$13.95B
Ratio de liquidité général
1.95
Couverture des intérêts
0.93
Dette/EBITDA
0.31
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$64.96
Prix actuel
$23.64
Marge de sécurité
+63.6%
Fourchette de juste valeur
$42.22 - $87.69
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-15.6%
Ratio P/B
1.97
P/FCF
36.58
Marge brute
30.1%
ROIC
-1.3%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
-1.3%
WACC
8.3%
ROIC − WACC
-9.6 pp
Le ROIC est inférieur au coût du capital — l'entreprise détruit de la valeur pour chaque dollar investi.
Critères d'analyse fondamentale
Réussi (10)
- Gross Margin 30.1%
- P/B Ratio 1.97
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Earnings Surprise avg 15.7%
- Share Dilution 0.1%
- Piotroski F-Score 6/9
Échoué (13)
- EPS shows upward trend
- Price CAGR -6.03%
- ROIC -1.3%
- P/FCF 36.58
- Operating Margin -2.4%
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -16.6%
- Revenue Growth 5Y -0.8%
- Analyst Consensus 25% Buy
- Net Margin Trend -9.3% vs -1.4%
Indisponible (4)
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Le nombre d'actions est stable
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Andrew P. Hider | CEO, President, Interim Group President of Medical Products & Therapies and Director | 48 |
| Mr. David S. Rosenbloom | Executive VP & General Counsel | 65 |
| Ms. Maria Soriano | Group President of Infusion Therapies & Platforms | - |
| Ms. Anita A. Zielinski | Interim CFO, Senior VP, Chief Accounting Officer & Controller | 52 |
| Mr. Charles Patel | Senior VP & Chief Information Officer | 55 |
| Mr. Kevin Moran | Vice President & Head of Investor Relations | - |
| Ms. Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | - |
| Ms. Cynthia Carlisle | Executive VP & Chief Human Resources Officer | 50 |
| Mr. James W. Borzi | Executive VP & Chief Supply Chain Officer | 62 |
| Mr. Steven P. Wallace | President of Advanced Surgery & Commercial Excellence | 45 |
Risque d'audit
3
Risque du conseil
2
Risque de rémunération
9
Risque droits des actionnaires
2
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-12
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-07-30
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-19
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for BAX, sourced from Markets Gazette.